Catabasis Pharma (CATB): Preview of Edasalonexent Proof-Of-Concept Study - Wedbush

October 13, 2016 8:25 AM EDT
Get Alerts CATB Hot Sheet
Price: $4.26 -0.7%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 30 | New: 8
Trade CATB Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Wedbush analyst, Heather Behanna, reiterated her Outperform rating on shares of Catabasis Pharma (NASDAQ: CATB) and her price target of $17 representing more than a 4x return on investment. The MoveDMD proof-of-concept study enrollment is complete and the analyst expects data in the first six weeks of 1Q17.

The analyst believes the science behind Catabasis’s NF-kB inhibitor, edasalonexent (CAT-1004), is sound and recent data from the World Muscle Society (WMS) suggests the compound is knocking down NF-kB in DMD boys. The analyst sees a compelling risk/reward for edasalonexent, with a best case scenario of a significant benefit (as measured by MR) at three months.

Boys will continue to be studied through a year to see functional changes and the analyst believes the six-month data can drive pivotal trial design and allow a greater time window for the benefit to be observed.

For an analyst ratings summary and ratings history on Catabasis click here. For more ratings news on Catabasis click here.

Shares of Catabasis closed at $4.71 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment